CAR T-cell therapy and bispecific antibodies have transformed the treatment landscape for many hematologic malignancies, offering new options for patients with relapsed or refractory disease. While both approaches harness the power of the immune system, they differ significantly in administration, accessibility, toxicity profiles, and durability of response. As evidence continues to evolve, clinicians are increasingly focused on one critical question: when should each therapy be used, and which patients are most likely to benefit?
The rise of immunotherapy has fundamentally changed how many blood cancers are treated.
For patients with diseases such as diffuse large B-cell lymphoma (DLBCL), multiple myeloma, acute lymphoblastic leukemia (ALL), and other hematologic malignancies, therapies that engage the immune system have produced outcomes that were difficult to imagine just a decade ago.
Two of the most important advances have been CAR T-cell therapy and bispecific antibodies.
Both approaches leverage T cells to attack cancer. Both have demonstrated impressive clinical activity. And both are rapidly expanding into earlier lines of treatment.
As more options become available, clinicians face an increasingly complex treatment landscape.
Quick Facts About CAR T-Cell Therapy and Bispecific Antibodies
-
Both therapies redirect the immune system to attack cancer cells.
-
CAR T-cell therapy uses a patient's own genetically engineered T cells.
-
Bispecific antibodies connect T cells directly to cancer cells using an off-the-shelf treatment.
-
Both approaches have demonstrated durable responses in relapsed and refractory hematologic malignancies.
-
Researchers continue to evaluate optimal sequencing and patient selection strategies.
What Is CAR T-Cell Therapy?
CAR T-cell therapy involves collecting a patient's T cells and genetically modifying them to recognize specific cancer-associated targets.
After the cells are engineered and expanded, they are infused back into the patient, where they seek out and destroy malignant cells.
CAR T-cell therapy has produced remarkable outcomes in several blood cancers, including:
-
Diffuse large B-cell lymphoma
-
Mantle cell lymphoma
-
Multiple myeloma
-
Acute lymphoblastic leukemia
One of the most appealing features of CAR T therapy is the potential for long-lasting remissions after a single treatment.
For some patients, responses have remained durable for years.
What Are Bispecific Antibodies?
Bispecific antibodies represent a different approach to immune engagement.
Rather than modifying a patient's T cells, these therapies are designed to bind both a cancer cell and a T cell simultaneously.
This creates a bridge that directs the immune system toward malignant cells.
Bispecific antibodies have rapidly emerged as an important treatment option in:
-
DLBCL
-
Follicular lymphoma
-
Multiple myeloma
-
Other B-cell malignancies
Unlike CAR T-cell therapy, bispecific antibodies are available as off-the-shelf products and can often be administered without the manufacturing delays associated with cellular therapy.
What Are the Advantages of CAR T-Cell Therapy?
CAR T-cell therapy offers several potential advantages:
Durable Responses
Many patients achieve deep and long-lasting remissions.
One-Time Treatment Approach
Unlike ongoing therapies, CAR T-cell treatment is generally administered as a single therapeutic intervention.
Expanding Clinical Experience
Growing real-world evidence continues to improve understanding of patient selection and toxicity management.
For appropriately selected patients, CAR T-cell therapy may offer the possibility of prolonged disease control after multiple prior therapies.
What Are the Advantages of Bispecific Antibodies?
Bispecific antibodies provide several practical benefits.
Immediate Availability
Treatment can often begin without waiting for cell collection and manufacturing.
Broader Accessibility
Many patients may be eligible for bispecific therapy even if they are not candidates for CAR T-cell therapy.
Flexible Treatment Strategies
Bispecific antibodies can often be incorporated into combination regimens and evaluated across different treatment settings.
These advantages have contributed to rapid adoption across multiple disease states.
How Do Toxicities Compare?
Both CAR T-cell therapy and bispecific antibodies can cause immune-related adverse events, including:
-
Cytokine release syndrome (CRS)
-
Immune effector cell-associated neurotoxicity syndrome (ICANS)
-
Infections
-
Cytopenias
However, the incidence, severity, and management strategies may differ between treatment approaches.
Ongoing advances in monitoring and supportive care have improved the ability to identify and manage these complications, allowing clinicians to safely administer these therapies to a broader range of patients.
Which Patients Should Receive CAR T-Cell Therapy vs Bispecific Antibodies?
This remains one of the most important unanswered questions in hematologic oncology.
Factors influencing treatment selection may include:
-
Disease subtype
-
Prior therapies
-
Disease burden
-
Patient fitness
-
Treatment goals
-
Access to specialized treatment centers
-
Urgency of treatment initiation
As both therapies continue moving into earlier lines of treatment, determining optimal sequencing strategies will become increasingly important.
Future research will likely help define which patients derive the greatest benefit from each approach.
What Clinicians Should Know
CAR T-cell therapy and bispecific antibodies are not competing technologies as much as they are complementary tools within a rapidly evolving treatment landscape.
Both approaches have expanded treatment options for patients with hematologic malignancies and are continuing to demonstrate impressive clinical activity across multiple disease settings.
The future challenge will not be choosing one over the other, but understanding how best to integrate these therapies into personalized treatment strategies that maximize efficacy while minimizing toxicity.
Continue the Discussion at LL&M Congress
The future of immune-based therapies will be explored during the session "Engineering Better Outcomes: Mechanistic Innovations in CAR T and Bispecific Therapy."
Faculty will examine resistance mechanisms, toxicity management strategies, emerging engineering approaches, and the latest evidence shaping the next generation of cellular and immune-based therapies.
Join experts at LL&M Congress to gain practical insights into how CAR T-cell therapy and bispecific antibodies are transforming care across hematologic malignancies. Register Now